Optimised AAV design, precision engineering and scalable production systems.
Design and optimise
We custom-build AAV plasmids with your transgene of interest, using our proprietary expression system to improve yield and quality.
We guide seamless transition from our scalable transient suspension production systems to our stable AAV packaging and producer cell lines. Our process development experts support you to expedite on-boarding of technologies and facilitate technology transfer.
License for manufacture
Our optimised transient AAV production platform and GMP-banked HEK293 cell line is available for license.
AAV at the edge of impossible
OXGENE technologies enable the broad adoption of cell and gene therapies. Our manufacturing systems facilitate high-titre AAV production in a scalable manner. Our early-access partnerships for AAV packaging cell line development allow easy adoption of our technologies, fully supported by our experts’ knowledge and experience. Our AAV production platform expedites clinical development timeframes from early product development to market approval.
All technologies are applied with our proprietary GMP-compliant, animal component free, optimal suspension-mode clonal cell line.
Our AAV production platform simplifies the genetic engineering process to reduce the timeframe between upstream production and market approval.
We are very excited to begin this collaboration [with OXGENE]. It’s one of many vital steps that we are taking to meet the demand for a broadening range of gene therapies. We hope that our approach will lead to quicker development of effective new therapies for patients.